Satralizumab, previously known as the SA-237 molecule, represents a promising option for neuromyelitis optica spectrum disorder and other neurological diseases . Emerging clinical trials have demonstrated https://bookmarks-hit.com/story25608999/satralizumab-a-deep-dive-into-sa-237-s-research-development